Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Total Current Liabilities
All obligations due within one year.
Pelthos Therapeutics Inc.AMEX: PTHS
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 389.6% from a year ago
Total current liabilities stood at $25M at the end of Q1 FY2026, up 389.6% from a year earlier and down 3.8% from the prior quarter. Over 3 fiscal years it compounded at +90.5% a year.
Context
- Total current liabilities amounted to 17.2% of total assets at the end of Q1 FY2026, down 543.3 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +389.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 25.99M USD
- Year-over-year change
- +536.6%
- 3-year CAGR
- +90.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.99M | +536.6% |
| FY2024 | 2024-12-31 | 4.08M | -37.6% |
| FY2023 | 2023-12-31 | 6.54M | +73.9% |
| FY2022 | 2022-12-31 | 3.76M | — |
Total Current Liabilities vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 total current liabilities of $25M is the highest of the 4 companies compared; the peer median is $9.02M.
- Its year-over-year change of +389.6% is the highest of 4, against a peer median of +137.5%.
- Total current liabilities amounts to 17.2% of total assets for PTHS, versus a peer median of 11.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $25M | +389.6% | +90.5% | 17.2% | |
| Mar 2026 | $10.96M | +95.2% | +13.7% | 35.5% | |
| Dec 2025 | $9.02M | +137.5% | +10.9% | 0.4% | |
| Mar 2026 | $1.22M | +245.0% | +49.9% | 11.3% | |
| Peer median (excluding PTHS) | $9.02M | +137.5% | +13.7% | 11.3% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.